Carregant...
Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data
BACKGROUND: Sanofi-Pasteur’s CYD-TDV is the only licensed dengue vaccine. Two phase three trials showed higher efficacy in seropositive than seronegative recipients. Hospital follow-up revealed increased hospitalisation in 2–5- year-old vaccinees, where serostatus and age effects were unresolved. ME...
Guardat en:
| Publicat a: | eLife |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
eLife Sciences Publications, Ltd
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8321579/ https://ncbi.nlm.nih.gov/pubmed/34219653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.65131 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|